Company intelligence / Profile preview

Benobio Co., Ltd.

Ownership: Private
Development stage: Preclinical

Overview

Benobio has developed novel small molecule inhibitors targeting bromodomain proteins such as BRD2 and BRD4 with potential applications in osteoarthritis, cancer, AMD, and NAFLD. The company has completed lead compound screenings for multiple indications including KRAS inhibition and COVID19 therapy. Clinical pipeline includes Phase 1 trials for age-related macular degeneration therapies[1][3][4].

Therapeutic areas: OphthalmologyOncologyGastroenterologyRheumatology
Modalities: Small moleculesChemical drugsEpigenetic modulators (BET inhibitors, BRD2 inhibitors)
Industry: Biotech

Drug pipeline

5 assets

BBC-1501

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Benobio Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Benobio Co., Ltd..

Explore the full profile